RheumMadness is back for its third season, and everyone who is crazy about rheumatology is welcome to play. That includes practicing rheumatologists, fellows, residents, medical students, advanced practice providers, other healthcare professionals and patients. Basically, if you are reading this article, you can play RheumMadness. RheumMadness is an online tournament in which a bracket of…
PHILADELPHIA—A session on social media in rheumatology at ACR Convergence 2022 focused on how to use social media to promote one’s work and collaborate on international research projects, as well as the use of podcasts in educating rheumatologists. Engaging at Conferences Jean Liew, MD, MS, assistant professor of medicine in the Section of Rheumatology at…
The U.S. government remains divided. Democrats hold the White House and the Senate by one vote, and Republicans lead the House. Amid this division, the ACR is watching possible areas to advance healthcare legislation. Meet the committees and members with the largest jurisdiction over healthcare policy.
In a joint letter, the ACR urges Congress to undergo comprehensive reform of the Medicare payment system and seek long-term payment solutions that will allow clinicians to continue to care for Medicare patients.
The Food & Drug Administration announced Jan. 26 that tixagevimab/cilgavimab (Evusheld) is no longer authorized for use in the U.S. The decision was based on new data suggesting that the treatment is unlikely to be active against the most common current SARS-CoV-2 variants.
Vaccinations against preventable diseases, including seasonal influenza, are strongly recommended for patients with rheumatoid arthritis (RA), who are at increased risk of infections as a result of underlying immune dysfunction and treatment-induced immunosuppression. Park et al. conducted this clinical trial to investigate whether discontinuing methotrexate for one week after seasonal influenza vaccination is noninferior to discontinuing it for two weeks after vaccination in patients with RA.
After years of legal disputes between drug makers, adalimumab-atto (Amjevita) biosimilar to adalimumab (Humira) is now available in the U.S. to treat rheumatoid arthritis and other diseases. Adalimumab-atto is the first of several biosimilars to adalimumab expected to become available in the U.S. in 2023.
PHILADELPHIA—A session on social media in rheumatology at ACR Convergence 2022 focused on how to use social media to promote one’s work and collaborate on international research projects, as well as the use of podcasts in educating rheumatologists. Engaging with Social Media at Conferences Jean Liew, MD, MS, assistant professor of medicine in the Section…
The ACR has compiled guidelines and tips on how to use the JW modifier and correctly bill Medicare for discarded drugs and biologicals. This modifier can be applied only to unused amounts from a single-dose vial or package.
This month, the CMS will begin steps to develop a drug pricing negotiation process as allowed by the Inflation Reduction Act. The ACR plans to participate in public comment opportunities.